A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient response without serious adverse effects.

Healthcare & Pharmaceuticalscategory· March 14, 2025 Drugmakers agree to participate in second round of price negotiations All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals ...

Delivering late stage therapeutic pipeline, building the next generation of radiopharmaceuticals, growing industry leading precision medicine business, expanding global infrastructure for product ...